One study analyzed asparaginase therapy in participants with a conglomerate of primarily solid tumors: melanoma, small cell lung cancer, non-small cell lung cancer, sarcoma, colon cancer, cholangiocarcinoma, renal cell carcinoma, bladder cancer, and malignancy with unknown primary. The gene discussed is ASPG; the disease is urinary bladder cancer.